Author: TipRanks Auto-Generated Newsdesk

Teva Pharmaceutical Industries (NYSE:TEVA), along with Formycon AG and Bioeq AG, has launched FYB201/Ranivisio in Europe as the first Lucentis biosimilar available in an EMA-approved pre-filled syringe. This move highlights Teva’s focus on innovation and its ongoing efforts to strengthen its ophthalmology offerings. See our latest analysis for Teva Pharmaceutical Industries. The recent European launch of FYB201/Ranivisio appears to have given Teva’s share price some renewed momentum, with a…Read More

Read More

Amazon is reportedly planning to lay off up to 30,000 corporate employees, representing nearly 10% of its corporate workforce. These significant cuts, expected to begin soon and impact the US, UK, and Canada, follow a period of cost-cutting and concerns about AI’s impact on jobs. Managers were recently warned to prepare for the upcoming announcements.Read More

Read More